Ge Healthcare Technologies Inc Stock Price, News & Analysis

GE HealthCare (GEHC), a Nasdaq-listed precision care innovation leader, will hold an investor day in New York City on November 21, 2024. The event will feature presentations on growth strategies, technology portfolio, and business vision via a live webcast.

GE HealthCare introduced SIGNA MAGNUS, a head-only MR scanner, to advance neuroscience research by overcoming limitations of whole-body MR systems. The system aims to enhance MR research in neurology, oncology, and psychiatry, offering superior gradient performance and deep-learning algorithms to explore brain microstructure and function. This innovation is set to revolutionize medical research and patient care, empowering researchers to uncover new parameters and biomarkers. SIGNA MAGNUS has the potential to impact patient outcomes and enhance our understanding of the human brain.

GE HealthCare (Nasdaq: GEHC) will have its Vice President and Chief Financial Officer, Jay Saccaro, presenting at upcoming investor conferences including Bank of America Securities 2024 Healthcare Conference in Las Vegas and Jefferies Global Healthcare Conference in New York. The events will take place on May 14, 2024, and June 5, 2024, respectively. Investors can access the events on the GE HealthCare website.

GE HealthCare unveiled Revolution RT, a new radiation therapy CT solution, along with AI-enhanced iRT platform and MIM Software portfolio, at ESTRO 2024 Congress. These innovations aim to optimize oncology care, reduce delays in diagnosis, and offer personalized treatment options. The company focuses on integrating AI-driven technologies to enhance precision, connectivity, and efficiency in cancer care, ultimately leading to better patient outcomes.

GE HealthCare reported first-quarter 2024 financial results with a 1% decline in revenues year-over-year. The net income margin increased to 8.0%, and adjusted EBIT margin was 14.7%. Diluted EPS rose to $0.81, with adjusted EPS at $0.90. Cash flow from operating activities was $419 million, with free cash flow at $274 million. The company repaid $150 million of debt in January 2024. GE HealthCare reaffirmed its full-year 2024 guidance.

GE HealthCare received FDA clearance for its Portrait VSM vital signs monitor, enhancing its connected patient monitoring solutions. The device offers precise readings for blood pressure, pulse rate, oxygen saturation, body temperature, and respiratory rate. It utilizes SuperSTAT non-invasive blood pressure algorithm and wireless connectivity for seamless EMR integration. The Portrait VSM integrates with Portrait Mobile for continuous patient monitoring, streamlining clinical workflows and enabling timely intervention to prevent patient deterioration.